Last updated 14 days ago

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

677 patients around the world
Available in Argentina, Chile, Mexico, United States, Brazil, Spain
Not provided
AstraZeneca
8Research sites
677Patients around the world
This study is for people with
Bladder Cancer
High Risk Muscle Invasive Bladder Cancer
Requirements for the patient
To 130 Years
All Gender
Medical requirements
Sites
Hospital Británico de Buenos Aires - CABA
Hospital Británico de Buenos Aires - CABA
Recruiting
Perdriel 74, CABA, Buenos Aires
Instituto Universitario CEMIC - CABA
Recruiting
Valdenegro 4337, C1430EFA Cdad. Autónoma de Buenos Aires, Argentina
Hospital Universitario Austral - Pilar
Recruiting
Av. Juan Domingo Perón 1500, Pilar, Buenos Aires
Instituto de Oncología de Rosario - IOR
Recruiting
Córdoba 2457, Rosario, Santa Fe
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Av. Crámer 1180, CABA, Buenos Aires
Centro de Investigación Pergamino SA
Recruiting
Av. de Mayo 1115, Pergamino, Buenos Aires
Hemato Oncólogos S.A.
Hemato Oncólogos S.A.
Recruiting
Calle 5b #43-12, Cali, Valle del Cauca,
UROLAP RESEARCH
Recruiting
Calle Ignacio Sandoval 1866-int. 19, Real Vista Hermosa, 28000 Colima, Col., Mexico
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy